Irreversible electroporation inhibits pro-cancer inflammatory signaling in triple negative breast cancer cells.

TitleIrreversible electroporation inhibits pro-cancer inflammatory signaling in triple negative breast cancer cells.
Publication TypeJournal Article
Year of Publication2017
AuthorsGoswami I, Coutermarsh-Ott S, Morrison RG, Allen IC, Davalos RV, Verbridge SS, Bickford LR
JournalBioelectrochemistry
Volume113
Pagination42-50
Date Published2017 Feb
ISSN1878-562X
KeywordsCell Death, Cytokines, Electricity, Electroporation, Humans, Inflammation, Signal Transduction, Triple Negative Breast Neoplasms
Abstract

Low-level electric fields have been demonstrated to induce spatial re-distribution of cell membrane receptors when applied for minutes or hours. However, there is limited literature on the influence on cell signaling with short transient high-amplitude pulses typically used in irreversible electroporation (IRE) for cancer treatment. Moreover, literature on signaling pertaining to immune cell trafficking after IRE is conflicting. We hypothesized that pulse parameters (field strength and exposure time) influence cell signaling and subsequently impact immune-cell trafficking. This hypothesis was tested in-vitro on triple negative breast cancer cells treated with IRE, where the effects of pulse parameters on key cell signaling factors were investigated. Importantly, real time PCR mRNA measurements and ELISA protein analyses revealed that thymic stromal lymphopoietin (TSLP) signaling was down regulated by electric field strengths above a critical threshold, irrespective of exposure times spanning those typically used clinically. Comparison with other treatments (thermal shock, chemical poration, kinase inhibitors) revealed that IRE has a unique effect on TSLP. Because TSLP signaling has been demonstrated to drive pro-cancerous immune cell phenotypes in breast and pancreatic cancers, our finding motivates further investigation into the potential use of IRE for induction of an anti-tumor immune response in vivo.

DOI10.1016/j.bioelechem.2016.09.003
Alternate JournalBioelectrochemistry
PubMed ID27693939
PubMed Central IDPMC5108677
Grant ListR03 DK105975 / DK / NIDDK NIH HHS / United States
R21 CA192042 / CA / NCI NIH HHS / United States
T32 OD010430 / OD / NIH HHS / United States

Person Type: